Treatment Landscape in HR+, HER2- MBC
ESMO 2023 Insights: "The RIGHT Choice Trial - 1L Ribociclib + ET vs. Combination Chemo in Aggressive HR+/HER2- Advanced Breast Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Hamdy Azim
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Hamdy Azim
Login to view comments.
Click here to Login
Treatment Landscape in HR+, HER2- MBC